for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avid Bioservices Inc

CDMO.OQ

Latest Trade

5.01USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.39

 - 

7.15

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Avid Bioservices Reports Q1 Loss Per Share $0.08

Sept 5 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR FIRST QUARTER FISCAL 2020 AND RECENT DEVELOPMENTS.Q1 LOSS PER SHARE $0.08.SEES FY 2020 REVENUE $64 MILLION TO $67 MILLION.Q1 REVENUE $15.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.4 MILLION.REPORTED $28.9 MILLION IN CASH AND CASH EQUIVALENTS AS OF JULY 31, 2019.FY2020 REVENUE VIEW $65.5 MILLION -- REFINITIV IBES DATA.

Avid Bioservices Enters Into Contract Manufacturing Agreements With New And Existing Customers

July 8 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES ENTERS INTO CONTRACT MANUFACTURING AGREEMENTS WITH NEW AND EXISTING CUSTOMERS.AVID BIOSERVICES INC - AGREEMENTS INCLUDE PROCESS TRANSFER, PROCESS DEVELOPMENT AND CLINICAL MANUFACTURING FOR NOVEL THERAPEUTIC CANDIDATES.AVID BIOSERVICES INC - AVID AND ITS CLIENT WILL IMMEDIATELY BEGIN PROCESS TRANSFER OF CELL LINE AND BENCH SCALE INFORMATION FOR PROGRAM.

Avid Bioservices Reports Q4 Loss Per Share $0.02

June 27 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR QUARTER AND FISCAL YEAR ENDED APRIL 30, 2019 AND RECENT DEVELOPMENTS.Q4 LOSS PER SHARE $0.02.Q4 REVENUE $17.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $15.7 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES DATA.SEES FY 2020 REVENUE $64 MILLION TO $67 MILLION.AS OF APRIL 30, 2019, REVENUE BACKLOG WAS APPROXIMATELY $46 MILLION.

Avid Bioservices Reaffirms Fiscal 2019 Guidance And Announces Upcoming Conference Participation

May 9 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES REAFFIRMS FISCAL 2019 GUIDANCE AND ANNOUNCES UPCOMING CONFERENCE PARTICIPATION.FY2019 REVENUE VIEW $52.0 MILLION -- REFINITIV IBES DATA.

Avid Bioservices Names Richard Hancock As Interim President And CEO

May 8 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES NAMES RICHARD B. HANCOCK AS INTERIM PRESIDENT AND CHIEF EXECUTIVE OFFICER.AVID BIOSERVICES INC - HANCOCK WILL ALSO CONTINUE TO SERVE ON AVID'S BOARD OF DIRECTORS.AVID BIOSERVICES INC - HANCOCK SUCCEEDS ROGER J. LIAS, PH.D., WHO HAS RESIGNED FROM COMPANY AND ITS BOARD OF DIRECTORS.AVID BIOSERVICES INC - IS COMMENCING A SEARCH FOR A PERMANENT CHIEF EXECUTIVE OFFICER..

Avid Bioservices Posts Q3 Loss Per Share of $0.05

March 11 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR THIRD QUARTER FISCAL 2019 AND RECENT DEVELOPMENTS.Q3 LOSS PER SHARE $0.05.Q3 REVENUE $13.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $12.7 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.EXPECTS TO END FISCAL YEAR WITHIN LOWER HALF OF ITS REVENUE GUIDANCE OF $51 MILLION - $55 MILLION.

Avid Bioservices Q2 Loss Per Share $0.05

Dec 10 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR SECOND QUARTER FISCAL 2019 AND RECENT DEVELOPMENTS.Q2 LOSS PER SHARE $0.05.SEES FY 2019 REVENUE $51 MILLION TO $55 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.AVID BIOSERVICES - REVENUE BACKLOG AS OF OCT. 31, 2018 WAS $36 MILLION, MAJORITY OF WHICH IS SEEN RECOGNIZING IN FY 2019.Q2 REVENUE CONTRACT MANUFACTURING REVENUE $10.2 MILLION VERSUS $12.8 MILLION.Q2 REVENUE VIEW $10.9 MILLION -- REFINITIV IBES DATA.

Avid Bioservices Q1 Loss Per Share $0.06

Sept 10 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR FIRST QUARTER FISCAL 2019 AND RECENT DEVELOPMENTS.SEES FY 2019 REVENUE $51 MILLION TO $55 MILLION.Q1 LOSS PER SHARE $0.06.AVID BIOSERVICES - FISCAL 2019 PROJECTED REVENUE OF $51 MILLION TO $55 MILLION REAFFIRMED.

Avid Bioservices Announces Appointment Of Daniel Hart As CFO

July 17 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES ANNOUNCES APPOINTMENT OF DANIEL HART AS CHIEF FINANCIAL OFFICER.AVID BIOSERVICES INC - HART MOST RECENTLY SERVED AS CFO OF ENO HOLDINGS INC.

Avid Bioservices Selected By Acumen Pharmaceuticals To Lead Process Development And Clinical Manufacture Of Novel Alzheimer's Disease Candidate

March 1 (Reuters) - Avid Bioservices Inc <CDMO.O>::AVID BIOSERVICES SELECTED BY ACUMEN PHARMACEUTICALS TO LEAD PROCESS DEVELOPMENT AND CLINICAL MANUFACTURE OF NOVEL ALZHEIMER’S DISEASE CANDIDATE.AVID BIOSERVICES - ACUMEN PHARMA SELECTED CO TO PROVIDE PROCESS DEVELOPMENT, CLINICAL MANUFACTURING SERVICES IN SUPPORT OF ACU193.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up